Drug intelligence / Profile preview

SER-203

Development stage: Unknown
Lead developer: Serina Therapeutics
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

SER-203 is a lead oncology candidate developed by Serina Therapeutics, Inc. It is a polymer therapeutic based on polyoxazoline (POZ) polymers. This technology is designed to be coupled to known drugs to modify their pharmacokinetics, thereby prolonging their activity and potentially improving their safety and efficacy. The platform also allows for targeted delivery to cancer cells.

Beyond the preview

Go deeper on SER-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-203.

Explore the full profile